SM
BCLI

Sabby Management’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Sabby Management’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-9,099
Closed -$27.3K – 60
2023
Q3 		$27.3K Sell
9,099
-75,426
-89% -$1.71M 0.02% 70
2023
Q2 		$2.61M Buy
+84,525
New +$3.5M 2.14% 3
2022
Q1 		– Sell
-34,214
Closed -$2.05M – 154
2021
Q4 		$2.05M Buy
34,214
+2,459
+8% +$121K 0.3% 53
2021
Q3 		$1.57M Buy
31,755
+15,565
+96% +$819K 0.21% 63
2021
Q2 		$923K Buy
16,190
+7,083
+78% +$378K 0.13% 87
2021
Q1 		$523K Buy
+9,107
New +$688K 0.1% 109
2019
Q3 		– Sell
-10,543
Closed -$622K – 95
2019
Q2 		$625K Sell
10,543
-39,137
-79% -$2.28M 0.79% 25
2019
Q1 		$3.23M Sell
49,680
-17,699
-26% -$1.01M 1.55% 10
2018
Q4 		$3.59M Buy
67,379
+6,915
+11% +$341K 0.79% 19
2018
Q3 		$3.46M Sell
60,464
-1,518
-2% -$91.8K 0.44% 33
2018
Q2 		$3.63M Buy
61,982
+60,494
+4,065% +$3.56M 0.56% 28
2018
Q1 		$70K Buy
+1,488
New +$74.9K 0.01% 139
2017
Q3 		– Sell
-1,115
Closed -$70K – 172
2017
Q2 		$70K Sell
1,115
-3,521
-76% -$217K ﹤0.01% 199
2017
Q1 		$296K Sell
4,636
-12,082
-72% -$629K 0.02% 204
2016
Q4 		$637K Sell
16,718
-12,915
-44% -$448K 0.04% 181
2016
Q3 		$1.06M Sell
29,633
-2,148
-7% -$80.4K 0.04% 178
2016
Q2 		$1.15M Sell
31,781
-1,098
-3% -$38.5K 0.06% 154
2016
Q1 		$1.32M Sell
32,879
-18,423
-36% -$677K 0.07% 136
2015
Q4 		$2.2M Sell
51,302
-5,521
-10% -$227K 0.12% 114
2015
Q3 		$1.95M Buy
56,823
+7,247
+15% +$341K 0.08% 159
2015
Q2 		$2.69M Sell
49,576
-44,393
-47% -$2.65M 0.1% 138
2015
Q1 		$6.27M Buy
+93,969
New +$5.94M 0.26% 68
2014
Q4 		– Sell
-53,884
Closed -$3.32K – 250
2014
Q3 		$3.32K Buy
+53,884
New +$3.32M 0.13% 75

Other funds holding BCLI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Sabby Management's BCLI Position: Q4 2023 in Review

Sabby Management sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2023, closing a stake of 9,099 shares — an estimated $27.3K sold.

Sabby Management first reported a position in BCLI in Q3 2014 and held it in 23 quarters. The position peaked at $6.27M in Q1 2015. 46 funds tracked by Wall St. Rank hold BCLI as of Q4 2023.

  • Sabby Management reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2023 after selling out during the quarter.
  • Sabby Management sold 9,099 BRAINSTORM CELL THERAPUTC shares in Q4 2023, an estimated $27.3K.
  • Sabby Management first reported a position in BRAINSTORM CELL THERAPUTC in Q3 2014 and held it in 23 quarters.
  • Sabby Management's BRAINSTORM CELL THERAPUTC position peaked at $6.27M in Q1 2015.
  • 46 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.